Navigation Links
Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
Date:11/16/2011

SAN MATEO, Calif., Nov. 16, 2011 /PRNewswire/ -- Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced top-line data from its recently completed Phase I clinical trial evaluating the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of subcutaneous bolus and subcutaneous infusion of cenderitide in patients with chronic heart failure. Nile is developing cenderitide as a 90-day outpatient treatment for heart failure patients following admission for acutely decompensated heart failure (ADHF), referred to as the "post-acute" treatment period.

The Phase I clinical trial was designed to understand the doses required to achieve pre-determined plasma levels of cenderitide when delivered through a subcutaneous infusion pump. The target cenderitide plasma levels were based on Nile's previous Phase 2 clinical trials in which cenderitide was delivered through continuous intravenous infusion. In Part A of the trial, 12 patients received two subcutaneous bolus injections of cenderitide.  In Part B of the trial, 34 patients received a 24-hour continuous subcutaneous infusion of either of two fixed doses of cenderitide or placebo. In Part C, 12 patients received a 24-hour continuous subcutaneous infusion of either a weight-based dose of cenderitide, or placebo. All infusions were delivered through subcutaneous pump technology of Medtronic, Inc. pursuant to the parties' February 2011 development collaboration agreement.

The top line results from the Phase 1 trial are as follows:

  • The primary end-point was met – cenderitide achieved target PK levels when delivered through Medtronic's subcutaneous pump technology;
  • 24 hour subcutaneous delivery of ceneritide through Medtronic's pump technology was well-tolerated, with no injection site irritation;
  • Subcutaneously delivered cenderitide has an acc
    '/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Nile Therapeutics Reports 2011 Third Quarter Financial Results
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Orexigen® Therapeutics Reports Third Quarter Financial Results
4. Silence Therapeutics Provides Corporate and Development Update
5. Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
6. Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011
7. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
8. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
9. United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
10. Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline
11. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Inc. (Nasdaq: ONTY ) announced today that ... present at the Rodman & Renshaw 16 th Annual ... on Tuesday, Sept. 9, 2014 at 2:05 p.m. Eastern. ... will be accessible by visiting the Oncothyreon website www.oncothyreon.com ... About Oncothyreon Oncothyreon is a biotechnology company ...
(Date:9/2/2014)... 2, 2014 Culot brings life ... lab management services  BioData, producer of Labguru, ... to announce the appointment of Louis Culot ... as VP Marketing and Business Development at BioDiscovery Inc., ... clinical applications. Previously, Culot worked for 17 ...
(Date:8/31/2014)... , Aug. 31, 2014 Wockhardt Limited ... Discovery program in Anti-Infective research when two of its ... Qualified Infectious Disease Product (QIDP) status from U.S. Food ... drugs which act against pathogens which have a high ... identified by Centre for Disease Control (a top U.S. ...
(Date:8/29/2014)... DIEGO, Aug. 29, 2014  Pfenex Inc. (NYSE ... the development of high-value and difficult to manufacture ... update and reported financial results for the second ... the successful completion of our initial public offering, ... our biosimilar product candidates, derived from our proprietary ...
Breaking Biology Technology:Louis Culot Appointed as BioData's CEO 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8
... deep underground carries no significant threat to human health, despite ... Researchers found that the risk of death from poisoning ... rocks is about one in 100 million far less ... from the University of Edinburgh studied historical data on deaths ...
... University-University of Oregon Center for Sustainable Materials Chemistry, born ... moving into a second phase under a new five-year, ... through its Centers of Chemical Innovation Program, will allow ... and development and boost efforts to translate basic-level discoveries ...
... The Albert and Mary Lasker Foundation, ... research, announced today the winners of the 2011 Lasker Awards ... Horwich for basic medical research, Tu Youyou for ... of Health for public service. The Lasker Awards – considered ...
Cached Biology Technology:Health fears over CO2 storage are unfounded, study shows 2Center for Sustainable Materials Chemistry gets Phase 2 NSF grant 2Center for Sustainable Materials Chemistry gets Phase 2 NSF grant 3Center for Sustainable Materials Chemistry gets Phase 2 NSF grant 42011 Lasker Awards Honor Medical Research Pioneers 22011 Lasker Awards Honor Medical Research Pioneers 32011 Lasker Awards Honor Medical Research Pioneers 42011 Lasker Awards Honor Medical Research Pioneers 52011 Lasker Awards Honor Medical Research Pioneers 62011 Lasker Awards Honor Medical Research Pioneers 7
(Date:9/1/2014)... and decisions of the Nomenclature Section of the XVIII ... July 2011. This meeting is held every six years ... the rules for naming algae, fungi and plants get ... naming the organisms they study. This is the primary ... for algae, fungi, and plants, which was published in ...
(Date:8/31/2014)... A fast-sensitive "electronic-nose" for sniffing the highly infectious bacteria ... stomach cramps, has been developed by a team at ... the research team has demonstrated that it is possible ... which would lead to rapid diagnosis of the ... could be possible to identify different strains of the ...
(Date:8/31/2014)... of satellite data from the last 19 years reveals that ... the coast of Antarctica to rise by 2cm more than ... of Southampton detected the rapid rise in sea-level by studying ... million square kilometres. , The melting of the ... has contributed an excess of around 350 gigatonnes of freshwater ...
Breaking Biology News(10 mins):Week-long meeting on naming algae, fungi, and plants recorded for posterity 2Scientists develop 'electronic nose' for rapid detection of C. diff infection 2
... created to provide a haven for both protected species ... Gothenburg have analysed species living on the seabed (benthic ... marine areas require special protection., , "It,s not possible ... park. That,s why I,ve done what experienced mushroom pickers ...
... This release is available in German . ... the carbohydrates they produce through photosynthesis in the leaves. However, ... heart to help transport this vital fuel. Instead, they use ... with colleagues from the Carnegie Institution for Science in California, ...
... of 34 institutions in 15 countries contributing to the measurements ... network, InGOS. , The network focuses on providing accurate information ... for a more vigorous climate action. In order to ... of greenhouse gas emissions is essential and not only ...
Cached Biology News:Life on Kosterhavet's seabed analyzed 2Sugar pump in plants identified 2Sugar pump in plants identified 3DTU is participating in a European network on measurement of greenhouse gases 2
... 1, active MW: 34.2kDa Formulation: 10mM ... Brij-35, 1mM dithiothreitiol with 50% glycerol ... to the Certificate of Analysis for ... salt precipitation followed by gel filtration ...
MitoScreen (JC-1) Kit , 100 tests Consult technical datasheet for details....
Thermal Printer Paper for Monolight(tm) Luminometer 1 each...
Conjugate Quality Control Evaluation Specificity: Conjugate Quality Control Evaluation ...
Biology Products: